Evoke Pharma (EVOK) Competitors $4.82 -0.44 (-8.37%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$4.82 0.00 (0.00%) As of 02/21/2025 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends EVOK vs. JATT, CMMB, COEP, PULM, RNXT, EQ, DARE, TRAW, CYTH, and CVMShould you be buying Evoke Pharma stock or one of its competitors? The main competitors of Evoke Pharma include JATT Acquisition (JATT), Chemomab Therapeutics (CMMB), Coeptis Therapeutics (COEP), Pulmatrix (PULM), RenovoRx (RNXT), Equillium (EQ), Daré Bioscience (DARE), Traws Pharma (TRAW), Cyclo Therapeutics (CYTH), and CEL-SCI (CVM). These companies are all part of the "pharmaceutical products" industry. Evoke Pharma vs. JATT Acquisition Chemomab Therapeutics Coeptis Therapeutics Pulmatrix RenovoRx Equillium Daré Bioscience Traws Pharma Cyclo Therapeutics CEL-SCI JATT Acquisition (NYSE:JATT) and Evoke Pharma (NASDAQ:EVOK) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, risk, media sentiment, valuation, dividends and profitability. Do insiders & institutionals hold more shares of JATT or EVOK? 48.0% of JATT Acquisition shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by insiders. Comparatively, 6.1% of Evoke Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has better valuation & earnings, JATT or EVOK? JATT Acquisition has higher earnings, but lower revenue than Evoke Pharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJATT AcquisitionN/AN/A$6.85MN/AN/AEvoke Pharma$5.18M1.39-$7.79M-$10.99-0.44 Is JATT or EVOK more profitable? JATT Acquisition has a net margin of 0.00% compared to Evoke Pharma's net margin of -71.32%. JATT Acquisition's return on equity of -49.58% beat Evoke Pharma's return on equity.Company Net Margins Return on Equity Return on Assets JATT AcquisitionN/A -49.58% 2.84% Evoke Pharma -71.32%-308.49%-53.66% Does the MarketBeat Community believe in JATT or EVOK? Evoke Pharma received 360 more outperform votes than JATT Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformJATT AcquisitionN/AN/AEvoke PharmaOutperform Votes36058.82% Underperform Votes25241.18% Does the media prefer JATT or EVOK? In the previous week, Evoke Pharma had 1 more articles in the media than JATT Acquisition. MarketBeat recorded 1 mentions for Evoke Pharma and 0 mentions for JATT Acquisition. JATT Acquisition's average media sentiment score of 0.00 equaled Evoke Pharma'saverage media sentiment score. Company Overall Sentiment JATT Acquisition Neutral Evoke Pharma Neutral SummaryJATT Acquisition beats Evoke Pharma on 6 of the 9 factors compared between the two stocks. Get Evoke Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for EVOK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVOK vs. The Competition Export to ExcelMetricEvoke PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.81M$7.06B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-0.445.8226.1519.13Price / Sales1.39268.05435.3370.72Price / CashN/A65.6738.0134.83Price / Book-0.526.717.644.62Net Income-$7.79M$138.55M$3.19B$245.94M7 Day Performance-6.04%-2.63%-2.11%-2.62%1 Month Performance12.09%-2.33%-0.49%-2.15%1 Year Performance-39.96%-5.33%16.44%12.95% Evoke Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVOKEvoke PharmaN/A$4.82-8.4%N/A-40.8%$7.81M$5.18M-0.444JATTJATT AcquisitionN/A$1.66-6.2%N/A-61.9%$28.64MN/A0.003Gap UpHigh Trading VolumeCMMBChemomab Therapeutics2.9666 of 5 stars$1.99+0.5%$7.50+276.9%+153.0%$28.58MN/A-1.9920Analyst ForecastNews CoverageCOEPCoeptis Therapeutics0.546 of 5 stars$11.57+2.0%N/A+7.5%$27.77MN/A-1.992News CoveragePULMPulmatrix0.0789 of 5 stars$7.58+4.7%N/A+404.0%$27.68M$10.01M-2.8720RNXTRenovoRx1.9 of 5 stars$1.15-0.9%$9.00+682.6%-24.3%$27.60MN/A-2.026Gap DownEQEquillium2.7188 of 5 stars$0.77-10.1%$5.00+549.4%-64.8%$27.28M$36.08M-5.5040Positive NewsDAREDaré Bioscience1.808 of 5 stars$3.10+4.4%$24.00+674.2%-27.0%$26.97M$1.88M-5.2530News CoverageTRAWTraws Pharma0.5212 of 5 stars$7.35-7.5%N/AN/A$26.84M$226,000.00-0.0517News CoverageGap DownCYTHCyclo Therapeutics0.9525 of 5 stars$0.93-22.0%$0.95+2.4%-45.8%$26.70M$1.08M-1.039News CoverageGap DownCVMCEL-SCIN/A$0.36-5.1%N/A-81.5%$26.65MN/A-0.7143News Coverage Related Companies and Tools Related Companies JATT Alternatives CMMB Alternatives COEP Alternatives PULM Alternatives RNXT Alternatives EQ Alternatives DARE Alternatives TRAW Alternatives CYTH Alternatives CVM Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EVOK) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evoke Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
